Am I wrong to read this as a reference to Fusion (a recent US$1.4billion buyout by Astra Zeneca)!"... Alpha-emitter therapies, such as those involving actinium-225 (Ac-225or 225Ac) and lead-212 (Pb-212 or 212Pb), are generatinginterest,BUT;
a) Their commercialsupply chains are still in the early development phase, and they arecurrently very difficult to source.
b) They are YET TOSHOWsafety and efficacy in late-stage trials, as opposed to betaemitters, like Cu-67, that have a long history of effectiveness in treatingsolid tumors...."
If so (and I think it is) - GREAT!
Ann: Clarity enters into Clinical Supply Agreement, page-5
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.22 |
Change
-0.140(2.61%) |
Mkt cap ! $1.625B | |||
| Open | High | Low | Value | Volume |
| $5.36 | $5.50 | $5.18 | $5.452M | 1.028M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6927 | $5.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.26 | 4319 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$5.22 |
Change
-0.140 ( 1.59 %) |
||||
| Open | High | Low | Volume | ||
| $5.34 | $5.49 | $5.19 | 94951 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| CU6 (ASX) Chart |